Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs. Its licensed products include canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States; AT-003, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats and dogs; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-017, a listeria based antigen delivery system for treating canine lymphoma in dogs; AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications; and AT-008, a therapeutic candidate for treating canine lymphoma in dogs in Europe. In addition, the company develops other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PETX
Previous Symbol
CUSIPN/A
Phone913-353-1000
Debt
Debt-to-Equity Ratio0.02
Current Ratio3.17
Quick Ratio2.70
Price-To-Earnings
Trailing P/E Ratio-6.34
Forward P/E Ratio-24.60
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.57 million
Price / Sales11.69
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.86 per share
Price / Book3.31
Profitability
EPS (Most Recent Fiscal Year)($0.97)
Net Income$-47,510,000.00
Net Margins-52.94%
Return on Equity-15.08%
Return on Assets-10.59%
Miscellaneous
Employees85
Outstanding Shares48,620,000
Market Cap$300.98 million
OptionableOptionable
Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions
What is Aratana Therapeutics' stock symbol?
Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."
How were Aratana Therapeutics' earnings last quarter?
Aratana Therapeutics Inc (NASDAQ:PETX) released its quarterly earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.16) by $0.03. The biopharmaceutical company had revenue of $21.56 million for the quarter, compared to analysts' expectations of $5.70 million. Aratana Therapeutics had a negative net margin of 52.94% and a negative return on equity of 15.08%. View Aratana Therapeutics' Earnings History.
When is Aratana Therapeutics' next earnings date?
What price target have analysts set for PETX?
4 Wall Street analysts have issued 12 month price objectives for Aratana Therapeutics' shares. Their predictions range from $7.00 to $10.00. On average, they anticipate Aratana Therapeutics' share price to reach $8.25 in the next year. This suggests a possible upside of 34.1% from the stock's current price. View Analyst Price Targets for Aratana Therapeutics.
What is the consensus analysts' recommendation for Aratana Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aratana Therapeutics.
Has Aratana Therapeutics been receiving favorable news coverage?
Media stories about PETX stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aratana Therapeutics earned a news sentiment score of 1.2 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next few days.
Who are some of Aratana Therapeutics' key competitors?
Some companies that are related to Aratana Therapeutics include Insmed (INSM), G1 Therapeutics (GTHX), Clovis Oncology (CLVS), Kiniksa Pharmaceuticals (KNSA), Uniqure (QURE), Apellis Pharmaceuticals (APLS), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), TherapeuticsMD (TXMD), Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Athenex (ATNX) and Crinetics Pharmaceuticals (CRNX).
Who are Aratana Therapeutics' key executives?
Aratana Therapeutics' management team includes the folowing people:
- Dr. Steven St. Peter, Co-Founder, Pres, CEO & Director (Age 52)
- Mr. Craig A. Tooman, CFO & Treasurer (Age 52)
- Mr. Brent A. Standridge, Chief Operating Officer (Age 60)
- Mr. John Paolucci, Director of Marketing
- Dr. Ernst Heinen, Chief Devel. Officer (Age 55)
Who are Aratana Therapeutics' major shareholders?
Aratana Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (12.30%), BlackRock Inc. (7.07%), Vanguard Group Inc. (4.20%), Vanguard Group Inc (4.20%), General American Investors Co. Inc. (3.93%) and Massachusetts Financial Services Co. MA (3.13%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.
Which major investors are selling Aratana Therapeutics stock?
PETX stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Renaissance Technologies LLC, Panagora Asset Management Inc., Morgan Stanley, Citadel Advisors LLC, Franklin Resources Inc. and TIAA CREF Investment Management LLC. Company insiders that have sold Aratana Therapeutics company stock in the last year include Brent Standridge, Craig A Tooman, Ernst Heinen and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.
Which major investors are buying Aratana Therapeutics stock?
PETX stock was acquired by a variety of institutional investors in the last quarter, including General American Investors Co. Inc., Dimensional Fund Advisors LP, Grandeur Peak Global Advisors LLC, Massachusetts Financial Services Co. MA, BlackRock Inc., Acadian Asset Management LLC, Vanguard Group Inc and Vanguard Group Inc.. View Insider Buying and Selling for Aratana Therapeutics.
How do I buy shares of Aratana Therapeutics?
Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aratana Therapeutics' stock price today?
One share of PETX stock can currently be purchased for approximately $6.15.
How big of a company is Aratana Therapeutics?
Aratana Therapeutics has a market capitalization of $300.98 million and generates $25.57 million in revenue each year. The biopharmaceutical company earns $-47,510,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Aratana Therapeutics employs 85 workers across the globe.
What is Aratana Therapeutics' official website?
How can I contact Aratana Therapeutics?
Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]
MarketBeat Community Rating for Aratana Therapeutics (NASDAQ PETX)
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days.
